Canadian DIN & Molecule SearchMolecules A–ZDrug ShortagesResourcesHealth Canada WeeklyRequest a Quote

OMNIPAQUE 350 755 MG

IOHEXOL : 755 MG · DIN 02172755 · GE HEALTHCARE CANADA INC

Health Canada status: MARKETED

What is OMNIPAQUE 350?

OMNIPAQUE 350 755 MG contains IOHEXOL : 755 MG. It is listed in the Health Canada Drug Product Database under DIN 02172755, held by GE HEALTHCARE CANADA INC, supplied as SOLUTION for INTRAVASCULAR ; ORAL administration. Health Canada currently lists it as marketed, status dated 29-Dec-2023. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.

What is OMNIPAQUE 350 used for?

Radiographic contrast medium for myelography, angiocardiography, CT enhancement, arteriography, venography, urography, arthrography, and GI tract imaging.

Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.

Product details and regulatory record

DIN02172755
Brand nameOMNIPAQUE 350
Generic / active ingredientIOHEXOL : 755 MG
ManufacturerGE HEALTHCARE CANADA INC
Strength755 MG
Dosage formSOLUTION
Route of administrationINTRAVASCULAR ; ORAL
ScheduleEthical
ATC codeV08AB02 IOHEXOL
BiosimilarNo
Health Canada statusMARKETED
Status date29-Dec-2023

How is it administered?

Dosage varies by procedure and patient age. Administered via subarachnoid, intravascular, oral, rectal, or intra-articular routes. Inject at or close to body temperature.

Included because it drives pack selection and wastage. Consult the monograph.

How is it stored and handled?

Protect from light. (Specific temperature range not in excerpt, but usually 15-30°C for this class).

How is it supplied?

Vials and bottles (specific sizes not listed in provided text excerpt).

Contraindications

Hypersensitivity to iohexol or any ingredient; clinically significant impairment of both hepatic and renal function.

Warnings and precautions

Serious/fatal anaphylactoid reactions possible. Observe for 30 mins. Risk of neurological complications if blood-brain barrier is disrupted. Avoid intracranial entry of bolus in myelography.

What can be used instead?

Other Canadian products sharing ATC code V08AB02 IOHEXOL. 3 of 8 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.

ProductStrengthFormManufacturerHealth Canada statusDIN
OMNIPAQUE 240518 MGSOLUTIONGE HEALTHCARE CANADA INCMARKETEDDIN 02172739
OMNIPAQUE 300647 MGSOLUTIONGE HEALTHCARE CANADA INCMARKETEDDIN 02172747
OMNIPAQUE 180388 MGSOLUTIONGE HEALTHCARE CANADA INCCANCELLED POST MARKETDIN 02172720
OMNIPAQUE 180 LIQ SAR 388MG/ML180 MGLIQUIDSANOFI CANADA, INC.CANCELLED POST MARKETDIN 02018098
OMNIPAQUE 240 LIQ IV SAR 518MG/ML240 MGLIQUIDSANOFI CANADA, INC.CANCELLED POST MARKETDIN 02018101
OMNIPAQUE 300 LIQ IV SAR 647MG/ML300 MGLIQUIDSANOFI CANADA, INC.CANCELLED POST MARKETDIN 02018128
OMNIPAQUE 350 LIQ IV 755MG/ML350 MGLIQUIDSANOFI CANADA, INC.CANCELLED POST MARKETDIN 02018136

Who else supplies IOHEXOL worldwide?

Nexara tracks national medicine registries and published price lists across multiple markets. IOHEXOL appears in 87 registered pack listings across 6 markets, published on 5 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.

Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.

How can I get it?

Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.

Request a quote for OMNIPAQUE 350

Ordering questions

Who can buy this from Nexara?

Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.

Is there a minimum order?

Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.

What is the lead time?

Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.

Can Nexara supply this for a clinical trial?

Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.

Request a quote for OMNIPAQUE 350

Health Canada Drug Product Database (DPD), DIN 02172755. Last reviewed 2026-09-08. Nexara Health is a licensed wholesaler and supplies licensed entities only; consumer orders are routed to a partner pharmacy.